SCHEMBL19470010

SCHEMBL19470010

COc1ccc2c(n1)N(CC(O)CN1CCC(N(C(=O)O)C(C)(C)C)CC1)C(=O)CC2

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 5/20 0.34
CHRM1 P11229 2/20 0.33
PRMT5 O14744 5/20 0.32
WDR77 Q9BQA1 5/20 0.32
KDM4E B2RXH2 1/20 0.31
ALDH1A1 P00352 1/20 0.31
NPSR1 Q6W5P4 1/20 0.31
SCN1A P35498 1/20 0.31
SCN5A Q14524 1/20 0.31
SCN9A Q15858 1/20 0.31
HTR2C P28335 1/20 0.31
MTNR1A P48039 1/20 0.31
MTNR1B P49286 1/20 0.31
HTR1A P08908 1/20 0.31
DRD2 P14416 1/20 0.31
HTR7 P34969 1/20 0.31
ADRB2 P07550 1/20 0.31
ADRB1 P08588 1/20 0.31
ADRB3 P13945 1/20 0.31
SLC2A1 P11166 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19470009 1.00 CYP2D6 (0.34) CYP2D6CHRM1PRMT5WDR77KDM4E
SCHEMBL909767 0.93 CYP2D6 (0.33) CYP2D6CHRM1PRMT5WDR77HTR2C
SCHEMBL3333076 0.83 CHRM1 (0.42) CHRM1PRMT5WDR77SCN1ASCN5A
SCHEMBL3328929 0.83 CHRM1 (0.42) CHRM1PRMT5WDR77SCN1ASCN5A
SCHEMBL4442971 0.81 DRD2 (0.40) CHRM1DRD2CCR5
SCHEMBL22168968 0.81 DRD2 (0.40) CHRM1DRD2CCR5
SCHEMBL3327481 0.75 HTR2C (0.34) PRMT5WDR77ALDH1A1HTR2CMTNR1A
SCHEMBL909967 0.72 KCNH2 (0.45) CYP2D6ALDH1A1DRD2SLC2A1
SCHEMBL910385 0.72 KCNH2 (0.45) CYP2D6ALDH1A1DRD2SLC2A1
SCHEMBL909966 0.72 KCNH2 (0.45) CYP2D6ALDH1A1DRD2SLC2A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3182973-B1 TRICYCLIC NITROGEN CONTAINING COMPOUNDS FOR TREATING NEISSERIA GONORRHOEA INFECTION GLAXOSMITHKLINE IP DEV LTD (GB) 2019-09-18 EP disclosed
US-20170304301-A1 TRICYCLIC NITROGEN CONTAINING COMPOUNDS FOR TREATING NEISSERIA GONORRHOEA INFECTION GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2017-10-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170304301-A1 TRICYCLIC NITROGEN CONTAINING COMPOUNDS FOR TREATING NEISSERIA GONORRHOEA INFECTION NME2, NNMT, NGLY1 CYP2D6 1650/4885CHRM1 2941/4885PRMT5 1509/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.